Fulvestrant

Alias: faslodex astrazeneca
cas registry number: 129453-61-8
assay: 97.0%~103.0%
molecular fomular: c32h47f5o3s
molecular weight: 606.77
density: 1.201 gcm3
melting point: 104-106º c
appearance: white powder
grade: pharmaceutical grade
storage: shading, confined preservation
manufacturer: gongchuang
delivery: ems, dhl, tnt, fedex, ups
2. Applications:
in particular 4 clinical trials in this setting did show similar efficacy to the other hormonal agents (aromatase inhibitors and tamoxifen) with good tolerability profile. Fulvestrant had a lower incidence of joint disorders.
many breast cancers are stimulated to grow by the female sex hormones oestrogen and progesterone. These breast cancers are called hormone sensitive or hormone receptor positive. Drugs that block the effects of these hormones can slow or stop the growth of the breast cancer cells. Fulvestrant stops oestrogen getting to the cancer cells by blocking oestrogen receptors and reducing the number of receptors the cancer cell has.